Encephalopathy - Pipeline Review, H1 2020

June 2020 | 81 pages | ID: ED4D3937857EN
Global Markets Direct

Abstracts

Encephalopathy - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalopathy - Pipeline Review, H1 2020, provides an overview of the Encephalopathy (Central Nervous System) pipeline landscape.
Encephalopathy is a term for any diffuse disease of the brain that alters brain function or structure. Symptoms include seizures, difficulty speaking or swallowing, trembling, involuntary twitching and muscle weakness. Causes include traumas or injuries, genetic, liver disease, hypoxic condition, Lyme disease and organ failure.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalopathy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Encephalopathy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Encephalopathy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 2, 10 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Encephalopathy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalopathy (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Encephalopathy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Encephalopathy (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Encephalopathy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Encephalopathy (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Encephalopathy (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Encephalopathy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Encephalopathy - Overview
Encephalopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Encephalopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalopathy - Companies Involved in Therapeutics Development
BrainRepair UG
Celularity Inc
Gene Therapy Research Institution Co Ltd
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl
Encephalopathy - Drug Profiles
Alda-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CL-2020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
diazoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target SLC2A1 for Glut1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
estetrol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate SLC2A1 for GLUT1 Deficiency Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-0006X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GWP-42003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MCC-950 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit IL-2 for Encephalopathy, Graft Versus Host Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Proteins for Hypoxic-Ischemic Brain Injury - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PSC-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
remestemcel-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLBM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Anemia and Hypoxic Ischemic Encephalopathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Encephalopathy and Periventricular Leukomalacia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalopathy - Dormant Projects
Encephalopathy - Discontinued Products
Encephalopathy - Product Development Milestones
Featured News & Press Releases
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Apr 02, 2019: Mithra receives orphan drug designation from FDA for E4 in neonatal encephalopathy treatment
Jun 09, 2017: Mithra Receives Orphan Drug Designation From EMA For E4 In Neonatal Encephalopathy
Mar 17, 2017: Sanofi awarded new funding to Monani Lab to study glucose transporter-1 deficiency syndrome
Dec 31, 2016: Defining the Spatial and Temporal Requirements for the Glucose Transporter-1 protein in Glut1 Deficiency Syndrome
Aug 06, 2015: GW Pharmaceuticals Receives FDA Fast Track and EMA Orphan Designations for Intravenous Cannabidiol in the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Apr 24, 2015: GW Pharmaceuticals Receives Orphan Drug Designation From FDA for Cannabidiol for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Encephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Encephalopathy - Pipeline by BrainRepair UG, H1 2020
Encephalopathy - Pipeline by Celularity Inc, H1 2020
Encephalopathy - Pipeline by Gene Therapy Research Institution Co Ltd, H1 2020
Encephalopathy - Pipeline by GW Pharmaceuticals Plc, H1 2020
Encephalopathy - Pipeline by Hope Biosciences LLC, H1 2020
Encephalopathy - Pipeline by Inflazome Ltd, H1 2020
Encephalopathy - Pipeline by JS Genetics Inc, H1 2020
Encephalopathy - Pipeline by Mesoblast Ltd, H1 2020
Encephalopathy - Pipeline by Mithra Pharmaceuticals SA, H1 2020
Encephalopathy - Pipeline by Mononuclear Therapeutics Ltd, H1 2020
Encephalopathy - Pipeline by Orphan Star Therapeutics LLC, H1 2020
Encephalopathy - Pipeline by Pfizer Inc, H1 2020
Encephalopathy - Pipeline by ProThera Biologics Inc, H1 2020
Encephalopathy - Pipeline by ReAlta Life Sciences Inc, H1 2020
Encephalopathy - Pipeline by SL Bigen Inc, H1 2020
Encephalopathy - Pipeline by Worphmed Srl, H1 2020
Encephalopathy - Dormant Projects, H1 2020
Encephalopathy - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Encephalopathy, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

BrainRepair UG
Celularity Inc
Gene Therapy Research Institution Co Ltd
GW Pharmaceuticals Plc
Hope Biosciences LLC
Inflazome Ltd
JS Genetics Inc
Mesoblast Ltd
Mithra Pharmaceuticals SA
Mononuclear Therapeutics Ltd
Orphan Star Therapeutics LLC
Pfizer Inc
ProThera Biologics Inc
ReAlta Life Sciences Inc
SL Bigen Inc
Worphmed Srl